CeriBell, Inc. - Common Stock (CBLL)

28.27
+1.31 (4.86%)
NASDAQ · Last Trade: Nov 4th, 12:46 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close26.96
Open27.11
Bid21.50
Ask26.50
Day's Range26.87 - 28.89
52 Week Range10.85 - 28.89
Volume689,002
Market Cap-
PE Ratio (TTM)-16.06
EPS (TTM)-1.8
Dividend & YieldN/A (N/A)
1 Month Average Volume553,153

Chart

About CeriBell, Inc. - Common Stock (CBLL)

CeriBell, Inc. is a healthcare company focused on developing innovative diagnostic solutions for neurological disorders. The company specializes in creating advanced technology and medical devices that support healthcare professionals in the accurate and timely diagnosis of conditions affecting the brain. By combining neuroscience research with cutting-edge software and hardware, CeriBell aims to enhance patient care, improve clinical outcomes, and facilitate better decision-making in the treatment of neurological diseases. Their commitment to research and innovation positions them as a leader in the field of neurology diagnostics. Read More

News & Press Releases

CeriBell Q3 Earnings Call Highlightsmarketbeat.com
CeriBell (NASDAQ:CBLL) reported third-quarter revenue growth of approximately 30% as the company added a record number of hospital accounts and increased usage of its seizure-monitoring platform among existing customers. Management also outlined plans to commercially launch its Delirium Monitoring S
Via MarketBeat · November 3, 2026
Ceribell (NASDAQ:CBLL) Falls After In-Line Q3 Revenue and Guidance Below Consensuschartmill.com
Via Chartmill · November 3, 2026
Ceribell Reports Third Quarter 2026 Financial Results
SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the third quarter ended September 30, 2026.
By Ceribell · Via GlobeNewswire · November 3, 2026
Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
Commercial launch follows successful pilot, with customers reporting improved clinical decision-making and greater confidence in care decisions
By Ceribell · Via GlobeNewswire · November 2, 2026
Ceribell Inc (NASDAQ:CBLL) Q1 Revenue Beats Estimates, Net Loss Widens, Full-Year Guidance Raisedchartmill.com
Via Chartmill · May 11, 2026
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SUNNYVALE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York City. The fireside chat will take place on Wednesday, November 11, 2026, at 7:00 a.m. Pacific Standard Time / 10:00 a.m. Eastern Standard Time.
By Ceribell · Via GlobeNewswire · October 28, 2026
Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026
SUNNYVALE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday, November 3, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 3, 2026.
By Ceribell · Via GlobeNewswire · October 20, 2026
Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
New clearance to further simplify bedside EEG interpretation and enable more informed interventions for patients of all ages across multiple indications
By Ceribell · Via GlobeNewswire · September 30, 2026
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Pushmarketbeat.com
CeriBell (NASDAQ:CBLL) outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base. Speaking at Canaccord’s 46th Annual Global Growth Conf
Via MarketBeat · August 12, 2026
CeriBell (CBLL) Q2 2026 Earnings Call Transcriptfool.com
Revenue surged 33% as hospital accounts expanded and delirium reimbursement neared launch.
Via The Motley Fool · August 10, 2026
CeriBell Q2 Earnings Call Highlightsmarketbeat.com
CeriBell (NASDAQ:CBLL) reported second-quarter 2026 revenue growth of 33% as increased utilization at existing hospital accounts and continued customer additions supported results. The company also raised its full-year revenue outlook and outlined plans to commercially launch its delirium-monitoring
Via MarketBeat · August 10, 2026
Ceribell Reports Second Quarter 2026 Financial Results
SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the second quarter ended June 30, 2026.
By Ceribell · Via GlobeNewswire · August 10, 2026
Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review
Neurology Review Software Enhancements Included as Part of Industry-Leading Ceribell Point-of-Care Brain Monitoring System
By Ceribell · Via GlobeNewswire · August 10, 2026
Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System
Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform
By Ceribell · Via GlobeNewswire · August 3, 2026
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
Medtech Market-Builder Thomas West and Health System Operator Sharon O’Keefe Join Ceribell as Point-of-Care Brain Monitoring Advances Toward Standard of Care
By Ceribell · Via GlobeNewswire · July 29, 2026
Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston. The fireside chat will take place on Wednesday, August 12, 2026, at 6:00 a.m. Pacific Daylight Time / 9:00 a.m. Eastern Daylight Time.
By Ceribell · Via GlobeNewswire · July 28, 2026
Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026
SUNNYVALE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Monday, August 10, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 10, 2026.
By Ceribell · Via GlobeNewswire · July 20, 2026
Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
Study published in leading critical care journal shows that higher AI-detected seizure burden is associated with increased odds of disability, further demonstrating the utility of the Ceribell System as a clinical decision-making tool
By Ceribell · Via GlobeNewswire · June 8, 2026
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 46th Annual Growth Stock Conference in Chicago. The presentation will take place on Wednesday, June 3, 2026, at 9:20 a.m. Pacific Daylight Time / 11:20 a.m. Central Daylight Time.
By Ceribell · Via GlobeNewswire · May 20, 2026
CeriBell Sees ‘Early Innings’ Growth as Hospital Accounts and Usage Hit Recordsmarketbeat.com
CeriBell (NASDAQ:CBLL) executives said the company’s first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlining early progress in new clinical areas including neonatal seizure monitoring and delirium. Speak
Via MarketBeat · May 15, 2026
CeriBell Q1 Earnings Call Highlightsmarketbeat.com
CeriBell (NASDAQ:CBLL) reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company’s strongest quarter of net new hospital additions since becoming public. On the company’s earnings call, Co-founder
Via MarketBeat · May 11, 2026
CeriBell (CBLL) Q1 2026 Earnings Transcriptfool.com
CeriBell (CBLL) Q1 2026 Earnings Transcript
Via The Motley Fool · May 11, 2026
Ceribell Reports First Quarter 2026 Financial Results
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the first quarter ended March 31, 2026.
By Ceribell · Via GlobeNewswire · May 11, 2026
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
SUNNYVALE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Bank of America Securities 2026 Health Care Conference. The fireside chat will take place on Wednesday, May 13, 2026, at 3:40 p.m. Pacific Standard Time / 6:40 p.m. Eastern Standard Time. 
By Ceribell · Via GlobeNewswire · April 29, 2026
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Monday, May 11, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 11, 2026.
By Ceribell · Via GlobeNewswire · April 20, 2026